Fund Holdings — Aisling Capital Management LP

Total Portfolio Value
$478.92M
Total Bought
$2.53M
Total Sold
$149.63M
Net Transaction
-$147.10M
Filing Period:
Securities
▲▼
SharesValue ($K)
Q3 2025
▲▼
Q4 2025
▲▼
Change
▲▼
Q3 2025
▲▼
Q4 2025
▲▼
Weight (%)
▲▼
Change
▲▼
BridgeBio Pharma Inc. (BBIO)(BBIO)6,089,6115,089,611-1,000,000316,294389,30481.29%+73,010
Monte Rosa Therapeutics Inc (GLUE)(GLUE)1,472,3311,472,331010,91023,0864.82%+12,176
Syndax Pharmaceuticals, Inc. (SNDX)(SNDX)1,316,8061,316,806020,26627,6665.78%+7,400
Urogen Pharma Ltd. (URGN)(URGN)0108,000+108,00002,5290.53%+2,529
CalciMedica, Inc. (CALC)(CALC)521,114521,11401,6033,4340.72%+1,831
Compass Pathways Plc (CMPS)(CMPS)1,198,4181,198,41806,8678,2691.73%+1,402
Bicara Therapeutics Inc. (BCAX)568,919568,91908,9839,5752.00%+592
BridgeBio Oncology Therapeutics (BBOT)(BBOT)564,625564,62506,5387,0691.48%+531
Scholar Rock Holding Corporation (SRRK)(SRRK)77,03177,03102,8693,3930.71%+525
Aclaris Therapeutics Inc (ACRS)(ACRS)434,455434,45508251,3080.27%+482
Marker Therapeutics, Inc. (MRKR)(MRKR)325,370325,37002904850.10%+194
OnKure Therapeutics, Inc. (OKUR)(OKUR)88,60788,60702442570.05%+13
Biomea Fusion Inc (BMEA)(BMEA)2,048,7572,048,75704,1382,5400.53%-1,598
Nuvation Bio Inc. (NUVB)(NUVB)2,960,6590-2,960,65910,9540—-10,954
Verona Pharma plc (VRNA)615,3520-615,35265,6640—-65,664
Page 1 of 1
Aisling Capital Management LP — 13F Holdings — Q4 2025 | TickerTrail